Introduction {#s1}
============

HSC-derived hematopoiesis has usually been studied in the setting of transplantation ([@bib8]; [@bib9]; [@bib18]; [@bib30]; [@bib40]; [@bib55]), an experimental paradigm that has been the foundation of hematopoietic research for decades ([@bib45]; [@bib48]) and which has established hallmark properties of HSCs such as multi-potency and self-renewal. However, while the transplantation assay has provided key insights, not the least with relevance for the clinical use in bone marrow (BM) transplantation, it might not accurately reflect the contribution of HSCs to ongoing and unperturbed steady state hematopoiesis. This is because transplantation is conducted under highly non-physiological conditions wherein HSCs are forced to proliferate to rebuild an entire hematopoietic hierarchy in a myeloablated bone marrow micro-environment. Therefore, there is a need to approach HSC biology also in more unperturbed settings.

While the overall structure of hematopoiesis is rather well established ([@bib11]), the degree by which HSCs contribute to adult hematopoiesis in the steady state is more unclear. This includes whether the proposed differentiation routes for the hematopoietic lineages are obligatory, or whether alternative/complementary pathways exist. Furthermore, cells of the different hematopoietic lineages have not only distinct homeostatic functions and maintenance mechanisms ([@bib7]; [@bib19]; [@bib38]) but also display dramatically different lifespans ([@bib20]; [@bib24]; [@bib50]; [@bib53]). As a consequence, the rates by which separate adult-derived blood cell lineages must be replenished differ substantially. At the extreme end, certain hematopoietic cell types generated during the fetal period appear devoid of replenishment from adult progenitors, and rather rely on homeostatic proliferation for their maintenance ([@bib22]; [@bib27]).

Recent developments of transgenic mouse models that allow for identification ([@bib1]; [@bib14]; [@bib21]) and evaluation of HSCs biology have facilitated studies of native in vivo hematopoiesis ([@bib12]; [@bib42]; [@bib47]; [@bib54]). Using one such model, we recently revealed that most adult HSCs are highly quiescent, which is strikingly different in the transplantation scenario ([@bib43]). Other models have been used for lineage tracing from HSCs ([@bib12]; [@bib42]; [@bib47]). In one of these, lineage tracing was conducted via random genetic integration of an inducible transposable genetic element, leading to the proposition that native hematopoiesis involves a large number of actively contributing progenitor cell clones, which are only rarely shared among hematopoietic lineages ([@bib47]). More common approaches for lineage tracing involve the use of cell type specific recombinases, that function to irreversibly mark a cell of interest and with time its descendants. While elegant and extensively used among developmental biologists, such approaches have only sparsely been applied to adult HSCs, and with seemingly contradictory results. Using a Tie2-driven model, Busch et al. concluded a substantial hematopoietic contribution/maintenance from progenitors rather than HSCs ([@bib12]), which at least to some extent would appear compatible with the results from [@bib47]. By contrast, Sawai et al. utilized a Pdzk1ip1-based CreERT2 system and suggested robust HSC labeling and hematopoiesis from adult HSCs ([@bib42]).

To try to assess these potential ambiguities, we here investigated the degree to which HSCs contribute to steady state adult hematopoiesis by using an inducible Fgd5-based HSC lineage tracing model ([@bib21]). We observed dramatic differences with regards to HSC contribution to adaptive immunity (slow) and the myeloerythroid lineages (fast), with HSCs contributing to the platelet lineage with the most rapid kinetics. The regeneration of terminal cell fates was closely mirrored at the level of each intermediate myeloerythroid precursor. These findings are consistent with adult HSCs as highly active contributors to multilineage hematopoiesis not only following transplantation, but also during the steady state. However, when approached in the situation of chronological aging, we noted diminished mature blood cell output from aged HSCs that could be traced to the first differentiation events from HSCs. These results suggest that the previously proposed fetal to adult switch ([@bib10]), in which HSCs alter their properties from more excessive proliferation/differatiation to a more dormant state in the adult, extends gradually throughout adulthood. As a consequence, the well-known numerical increase of HSCs with age ([@bib32]; [@bib39]; [@bib46]) appears to represent a physiologically relevant mechanism to account for reduced HSC differentiation with age.

Results {#s2}
=======

Fgd5-CreERT2-based lineage tracing allows for assessment of HSC contributions to unperturbed hematopoiesis {#s2-1}
----------------------------------------------------------------------------------------------------------

Using a transcriptome based screen of more than 40 different hematopoietic cell types, Fgd5 (FYVE, RhoGEF and PH domain containing 5) was identified as a HSC-expressed gene that is rapidly downregulated upon differentiation. That Fgd5 expression marks all HSCs was confirmed through functional studies using an Fgd5 knock-in reporter strain ([@bib21]). To further detail the HSC specificity of Fgd5, we first acquired transcriptome data from 11,581 individual lineage-marker negative, c-kit positive and CD45 positive bone marrow cells (Lin^-^kit^+^). The Lin^-^kit^+^ population contains a range of different immature hematopoietic progenitor cells ([@bib37]). Therefore, Lin^-^kit^+^ cells provided a benchmark to which other more defined/specific hematopoietic progenitor subsets could be compared. Next, we took advantage of an Fgd5 reporter strain in which a ZsGreen-2A-CreERT2 allele was knocked into the endogenous *Fgd5* locus (hereafter *Fgd5^CreERT2/+^* mice) ([Figure 1B](#fig1){ref-type="fig"}) ([@bib21]). We sorted either Lin^-^kit^+^Fgd5^+^ cells ([Figure 1A](#fig1){ref-type="fig"} middle; 793 cells, Fgd5^+^), or Fgd5^+^ cells with a stringent Lin^-^kit^+^Sca-1^+^CD48^-^CD150^+^ HSC phenotype ([Figure 1A](#fig1){ref-type="fig"} right, 519 cells, HSC-Fgd5^+^). All Fgd5^+^ and HSC-Fgd5^+^ data were aggregated with the Lin^-^kit^+^ transcriptome data, which was followed by identification of the most significant gene vectors using principal component analysis (PCA). Data was then visualized using t-distributed stochastic neighbor embedding (tSNE) dimensionality reduction ([Figure 1A](#fig1){ref-type="fig"}). Lin^-^kit^+^ cells were extensively scattered across the two dimensions ([Figure 1A](#fig1){ref-type="fig"}, left), in agreement with the heterogeneity of these cells. By contrast, Fgd5^+^ cells, regardless if sorted based on additional HSC markers, formed a distinct and highly overlapping cluster ([Figure 1A](#fig1){ref-type="fig"}, middle and right). This cluster localized to a region with very few cells when evaluating Lin^-^kit^+^ cells ([Figure 1A](#fig1){ref-type="fig"}, left, dotted area), emphasizing the HSC-specificity of the Fgd5 reporter and the low HSC frequency within the larger Lin^-^kit^+^ fraction.

![Fgd5-CreERT2 specifically labels HSCs and Fgd5-mediated label progresses throughout the hematopoietic system.\
(**A**) Lineage negative c-kit^+^ cells (Lin^-^c-kit^+^, left), lineage negative c-kit^+^ Fgd5^+^ cells (Fgd5^+^, middle) and lineage negative Fgd5^+^c-kit^+^Sca-1^+^CD150^+^CD48^-^ cells (HSC-Fgd5^+^, right) were isolated and subjected to single cell RNA-sequencing. The data was aggregated and visualized in a two-dimensional scatter plot after PCA and tSNE dimensionality reduction. Fgd5^+^ cells are highlighted in pink (middle), Lin^-^c-kit^+^ cells are highlighted in black (left plot) and HSC-Fgd5^+^ cells are highlighted in blue (right plot). The area that Fgd5^+^ cells occupy in relation to the transcriptomes of Lin^-^c-kit^+^ cells and HSC-Fgd5^+^ cells is marked by a dotted line (left and right plots). (**B**) Schematic representation of the *Fgd5^CreERT2/+^; Rosa26^lsl-Tomato/+^* model. ZsGreen and CreERT2 are expressed from the Fgd5 locus and expression of a Tomato allele is driven by a CAG promoter from the Rosa26 locus and is preceded by a LoxP flanked STOP cassette. (**C**) Model description; HSCs selectively and continuously express ZsGreen in an Fgd5-dependent manner. Upon Tamoxifen (TAM) administration, HSCs express Tomato and expression of Tomato label is inherited by all progeny of Tomato-expressing HSCs. (**D**) Representative FACS plots showing Tomato label in BM HSPCs from *Fgd5^CreERT2/+^; Rosa26^lsl-Tomato/+^* mice that were injected with Tamoxifen 48 hr prior to analysis. (D, lower right) Representative histograms depicting Tomato label in PB cells at various time points after the start of Tamoxifen administration from mice in [Figure 3B](#fig3){ref-type="fig"} (T cells 48 weeks, B cells 25 weeks, granulocytes and monocytes 8 weeks, platelets and erythrocytes 13 weeks). Numbers in FACS plots depict the mean % of Tomato labeled cells ± SD (n = 5) and dashed lines in histograms indicates the boundary for Tomato positivity. (**E**) FACS plots showing H2B-mCherry label retention and Tomato labeling in Lineage^-^c-kit^+^CD150^+^CD48^-^ and Sca1^+^ or Sca1^-^ cells from a representative mouse that had diluted H2B-mCherry label for 5 weeks and were injected with Tamoxifen 5 days prior to analysis (n = 3; 14--19 weeks old at analysis). (**F**) The fraction of donor-derived cells among different blood cell lineages was assessed in individual mice 16 weeks post-transplantation in recipients of 5 Tomato^+^ (n = 8) or 5 Tomato^-^ (n = 7) HSCs. Abbreviations: 2A, 2A self-cleaving peptide; CAG, CAG promoter; loxP, LoxP site.](elife-41258-fig1){#fig1}

We next generated a lineage tracing model by crossing *Fgd5^CreERT2/+^* mice to *Rosa26-Lox-Stop-Lox-Tomato* mice (hereafter *Rosa26^lsl-Tomato/+^*) ([Figure 1B](#fig1){ref-type="fig"}). In this model, HSCs can be identified based on ZsGreen expression, while Tamoxifen administration leads to irreversible and heritable Tomato labeling of HSCs and, over time, their offspring ([Figure 1C](#fig1){ref-type="fig"}). To confirm the model, we evaluated Tomato label in HSC and BM progenitor cells 48 hr after a single injection (1x) of Tamoxifen. This revealed labeling of a fraction of candidate HSCs, with virtually no labeling in other c-kit^+^ progenitor fractions ([Figure 1D](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). This established HSC specific labeling and a relatively low differentiation rate of HSCs in steady state ([@bib43]; [@bib54]). To illustrate our ability to detect Tomato label in peripheral blood (PB) cells, we assessed Tomato expression in defined cell types from mice that had received Tamoxifen 8--48 weeks previously ([Figure 1D](#fig1){ref-type="fig"}, lower right). Complementary to immunophenotypic identification of initially labeled BM cells as HSCs ([Figure 1D](#fig1){ref-type="fig"} and data not shown), we evaluated the proliferation history of Tomato labeled HSPCs 5 days after a pulse of Tomato labeling by evaluation of transgenic H2B-mCherry label retention ([Figure 1E](#fig1){ref-type="fig"}) ([@bib43]). Among HSCs, this revealed a strong correlation between a restricted proliferative history and Tomato labeling. Of note, a single dose of Tamoxifen was insufficient to label all candidate Fgd5-expressing HSCs ([Figure 1E](#fig1){ref-type="fig"} and data not shown).

Finally, to corroborate that Tomato labeled phenotypic HSCs are bona fide HSCs, we injected mice with Tamoxifen and isolated candidate Tomato positive and negative HSCs 48 hr later. Sorted cells were transplanted at limiting dilution (5 cells/mouse). This revealed long-term multilineage reconstitution in 5/8 recipients transplanted with Tomato^+^ HSCs ([Figure 1F](#fig1){ref-type="fig"}).

Fgd5-lineage tracing reveals that HSCs generate different types of hematopoietic progeny with distinct kinetics {#s2-2}
---------------------------------------------------------------------------------------------------------------

Encouraged by the highly specific HSC label observed after Tamoxifen administration to *Fgd5^CreERT2/+^; Rosa26^lsl-Tomato/+^* mice ([Figure 1](#fig1){ref-type="fig"}), we next set out to perform label tracing studies of hematopoietic generation from HSCs. For this, we labeled cohorts of *Fgd5^CreERT2/+^; Rosa26^lsl-Tomato/+^* mice with one injection of Tamoxifen and chased groups of mice for different periods of time up to 83 weeks after labeling. At end point analyses, the fraction of Tomato^+^ cells was determined in various hematopoietic compartments to assess the HSC contribution to progenitor pools and mature blood cell subsets ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). The frequencies of Tomato^+^ cells for each investigated subset were next related to the fraction of Tomato labeled HSCs ([Figure 2A](#fig2){ref-type="fig"}, mean 13% ± 9%) in individual mice ([Figure 2B](#fig2){ref-type="fig"}, and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). The fraction of labeled HSCs was generally higher in mice analyzed beyond 4 days of chase compared to mice analyzed after shorter chase periods. However, no further increase in HSC labeling was noted after longer periods of chase ([Figure 2A](#fig2){ref-type="fig"}).

![Fgd5-CreERT2 mediated lineage tracing reveals robust HSC contribution with distinct kinetics into hematopoietic cell subsets in steady state and after transplantation.\
Cohorts of *Fgd5^CreERT2/+^; Rosa26^lsl-Tomato/+^* mice were chased for up to 83 weeks after receiving one Tamoxifen injection before endpoint analysis of the % of Tomato^+^ cells in HSCs (**A**) and hematopoietic progenitor and PB cell subsets (**B**). The fraction of Tomato^+^ cells in each indicated hematopoietic cell subset was divided by the % Tomato label in HSCs in corresponding mice to determine the ratio of Tomato^+^ cells relative to HSCs in individual mice. The average ratio is plotted according to time after the Tamoxifen (TAM) injection and displayed in a heat map format. Mice were analyzed at 1--4 days (n = 18) and at 4 (n = 7), 8 (n = 8), 12 (n = 8), 16 (n = 4), 28 (n = 4), 32 (n = 5) and 83 (n = 3) weeks after the Tamoxifen injection. All mice were between 5 and 11 weeks old at the time of Tamoxifen injection. (**C**) PCA plot of multiplexed qRT-PCR data for 48 genes from triplicates of 10 cells from each of the indicated populations. Ellipses show an area where a new observation from the same group would position itself with a probability of 0.95. Numbers indicate the % of variance in the total data set that the respective PC explains. (**D**) For individual animals, the % of Tomato^+^ cells in PB cell types was divided by the % of Tomato^+^ cells in the indicated progenitor cell types and this value was plotted according to the duration of the chase period. Symbols represent individual mice (number of mice analyzed as in A and B). A dashed line is drawn to indicate an equilibrium-ratio of 1. (**E**) Ratios calculated as in B and plotted according to the number of weeks after transplantation or after the start of Tamoxifen administration for steady state/native mice (n = 3 for WBM tx in CD45 depleted, n = 5 for WBM tx in irradiated, n = 11 for HSC tx in irradiated, n = 4--8 for 1x TAM, n = 4--9 for continous TAM). All *Fgd5^CreERT2/+^; Rosa26^lsl-Tomato/+^* mice/cells were between 5 and 11 weeks old at the time of Tamoxifen administration or when used as cell donors for transplantation.](elife-41258-fig2){#fig2}

First, we investigated Tomato label progression into the immature lineage negative, Sca-1 positive and c-kit positive (LSK) compartment, fractionated further using the Slam markers CD48 and CD150 ([@bib28]) ([Figure 2B](#fig2){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). We used this approach to identify HSCs (LSKCD150^+^CD48^-^) and different multipotent progenitor fractions (MPPs: LSKCD150^-^CD48^-^, MPP^2^: LSKCD150^+^CD48^+^, MPP^3/4^: LSKCD150^-^CD48^+^).

LSKCD150^-^CD48^-^ MPPs are immature multipotent progenitors distinguished from HSCs by their limited self-renewal potential ([@bib28]; [@bib29]; [@bib49]). Of the evaluated progenitor subsets in our work, this subset was generated from HSCs with the fastest kinetics, with near equilibrium to HSC label reached already by 4 weeks ([Figure 2B](#fig2){ref-type="fig"}).

MPP^2^ cells represent a rare subset of cells with more undefined lineage/developmental affiliations. This prompted us to first elucidate their developmental potential. First, we aimed to place these cells within a transcriptional framework established by other, more established, hematopoietic progenitors. For this, we obtained gene expression data from a panel of defined stem and progenitor cells and MPP^2^ cells using a multiplexed qRT-PCR approach for 48 genes, selected to include cell surface markers, cell cycle regulators and transcription factors associated with hematopoiesis ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). Visualization of this data using PCA revealed that MPP^2^ cells clustered closely to Meg/E progenitors ([Figure 2C](#fig2){ref-type="fig"}). Consistent with a close association to the Meg/E lineages, short-term (6 days) culture experiments revealed a more robust generation of both megakaryocyte and erythroid containing colonies from MPP^2^s compared to other LSK subsets ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). When investigating Tomato label progression, MPP^2^ cells reached label equilibrium with HSCs after 32 weeks in 1x injected mice ([Figure 2B](#fig2){ref-type="fig"}).

MPP^3/4^ cells lack, for the most part, Meg/E lineage potential ([@bib2]; [@bib5]; [@bib36]; [@bib37]). MPP^3/4^ cells acquired Tomato label with much slower kinetics compared to other LSK fractions ([Figure 2B](#fig2){ref-type="fig"}).

Of the distinct progenitor fractions within the Lin^-^kit^+^ fraction ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}), megakaryocyte progenitors (MkP) acquired label with the fastest kinetics, reaching label equilibrium with HSCs after 32 weeks. Other myeloerythroid progenitors, including pre-megakaryocytic/erythroid (preMeg/E), pre-colony forming unit-erythroid (pre CFU-E) and pre-granulocyte-macrophage (preGM) progenitors acquired Tomato label with very similar kinetics despite their distinct lineage affiliations, although they never quite reached an equilibrium with HSCs throughout the course of the experiments ([Figure 2B](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}).

Mature effector cells represent the terminal progeny of HSCs. We observed distinct generation kinetics for different lineages ([Figure 2B](#fig2){ref-type="fig"}). First, we made the general observation that myeloerythroid cells acquired label more rapidly than lymphoid cells. Among the myeloid subsets, platelets acquired Tomato label with the fastest kinetics, followed by granulocytes and erythrocytes. Among lymphoid cell types, NK cells displayed faster labeling kinetics followed by B cells. T cells showed the slowest labeling kinetics among lymphoid cells and CD4^+^ T cells acquired label faster than CD8^+^ T cells ([Figure 2B](#fig2){ref-type="fig"}). Because the frequency of Tomato^+^ cells increased over time in all evaluated lineages, this data demonstrate a continuous contribution of HSCs to all hematopoietic lineages.

While multiple studies have defined populations of hematopoietic progenitors that associate with distinct developmental and/or stages of differentiation ([@bib11]), it is unknown whether such described progenitors are obligatory intermediates and/or their quantitative association relative to their anticipated mature offspring. Therefore, we interrogated the relationships between the rates of (re)generation of candidate committed myeloerythroid progenitors to those of their proposed mature cell lineage. At the earliest time points evaluated, we observed for all evaluated fractions a higher label in their corresponding progenitors ([Figure 2D](#fig2){ref-type="fig"}). However, this was resolved during the course of the experiments and reached similar equilibrium ratios for all evaluated lineages, although the erythroid lineage displayed somewhat slower kinetics ([Figure 2D](#fig2){ref-type="fig"}). Collectively, these experiments are in line with the view that progenitor generation precedes the generation of mature cells and that previously proposed progenitors appears to be, at least for the most part, obligatory intermediates.

Hematopoiesis after transplantation of HSCs is fundamentally different from unperturbed hematopoiesis ([@bib12]; [@bib47]). However, to what extent the pre-conditioning regimen and co-transplantation of mature cells and progenitors influence on hematopoiesis from HSCs is less established. Therefore, we next transplanted wild type recipient mice on continuous Tamoxifen diet with purified *Fgd5^CreERT2/+^; Rosa26^lsl-Tomato/+^* HSCs or WBM cells. Here, recipient mice were pre-conditioned by either lethal irradiation or antibody mediated CD45-depletion ([@bib34]). Due to the HSC specificity of the model, this approach allowed us to monitor the kinetics of the HSC contribution to all lineages after transplantation and compare it to the HSC contribution in steady state ([Figure 2E](#fig2){ref-type="fig"}). Compared to steady state, label progression in transplanted mice were faster ([Figure 2E](#fig2){ref-type="fig"}). When label progression kinetics was compared between HSC and WBM transplanted animals, HSC transplantation resulted in faster label progression, especially into the B cell lineage ([Figure 2E](#fig2){ref-type="fig"}). This likely reflects a significant contribution to the regeneration of the B cell lineage by co-transplanted long-lived B-lineage progenitors and mature cells after WBM transplantation. Comparison of label progression after WBM transplantation into irradiated or non-irradiated/antibody-mediated conditioned recipient mice revealed similar label progression kinetics into most mature lineages, with the exception of platelets that displayed a faster label progression in irradiated mice. This suggests that progenitors for platelets are more effectively ablated by irradiation than antibody-mediated pre-conditioning.

Fgd5-mediated HSC lineage tracing corroborates the fetal/juvenile origin of Langerhans cells, B1a B cells and brain microglial cells {#s2-3}
------------------------------------------------------------------------------------------------------------------------------------

While a labeling regimen of one Tamoxifen injection allows for accurate kinetic evaluations ([Figure 2A--B,D](#fig2){ref-type="fig"}), this experimental strategy labels only a fraction of HSCs ([Figure 1E](#fig1){ref-type="fig"} and [Figure 2A](#fig2){ref-type="fig"}) and thus necessitates correlation of label in HSCs to other evaluated cell subsets ([@bib12]) ([Figure 2B](#fig2){ref-type="fig"}). If the original HSC label is low, this might as a consequence not allow for evaluation of the activity of the entire pool of HSCs.

To explore whether we could label the HSC pool more extensively, *Fgd5^CreERT2/+^; Rosa26^lsl-Tomato/+^* mice were fed Tamoxifen containing food pellets for 16 weeks. To rule out adverse effects of prolonged Tamoxifen treatment on HSC proliferation, these experiments were preceded by a control label retaining experiment using *Col1a1^tetO-H2B-mCherry/tetO-H2B-mCherry^; ROSA26^rtTA/rtT^* mice ([@bib43]). Following H2B-mCherry induction with Doxycycline, mice were chased for 5 weeks in the presence or absence of Tamoxifen. Prolonged Tamoxifen treatment did not induce any additional proliferation within the HSC compartment, while more differentiated progenitors had readily proliferated in both settings ([Figure 3A](#fig3){ref-type="fig"}).

![Fgd5-mediated lineage tracing after complete HSC labeling reveals limited adult HSCs contribution to tissue-resident immune cell subsets.\
(**A**) H2B-mCherry label retention in HSCs and myeloid progenitors after 5 weeks of chase in mice continuously fed Tamoxifen (TAM) containing food (blue histograms, n = 7) or normal food (red histograms, n = 6) during the chase period. Green histograms depict an unlabeled control. Dashed lines indicate the boundary for H2B-mCherry positivity. Lineage negative c-kit^+^Sca1^-^ cells are denoted as myeloid progenitors. (**B**) Cohorts of *Fgd5^CreERT2/+^; Rosa26^lsl-Tomato/+^* mice were continuously fed Tamoxifen food for 16 weeks (TAM phase) and thereafter normal chow during a chase phase of 32 weeks (n = 5) or 41 weeks (n = 4). During the TAM and chase phases, PB was regularly analyzed for Tomato label in the indicated subsets. Data points indicate the average % of Tomato label in each indicated subset. (**C--E**) Endpoint analysis, after 41 weeks chase, in mice from [Figure 3B](#fig3){ref-type="fig"} (n = 3). (**C**) Representative FACS plots showing the gating strategy to identify HSCs in lineage negative BM cells (left, middle) and depiction of the Tomato label in HSCs (right, red histogram) compared to an unlabeled control (blue histogram). Dashed line indicates the boundary for Tomato positivity, arrows indicate the gating strategy. (**D**) Representative FACS plots of cells isolated from skin tissue (epidermis) or the peritoneal cavity. Histograms show Tomato label (bottom left and right) or ZsGreen label (bottom middle) in the indicated subsets. Dashed line indicate the boundary for Tomato positivity, arrows indicate the gating hierarchy, gates and corresponding histograms are color matched. (**E**) Representative confocal images of the brain. (Left) IBA1 positive cells (green) are not labeled with Tomato (red, middle) while blood vessels are labeled with Tomato (middle). (Right) Merged images display both IBA1 staining and Tomato label. Scale bar = 50 μm. Mice in B-E were 5--6 weeks old at the start of Tamoxifen administration.](elife-41258-fig3){#fig3}

The 16 weeks labeling period was followed by an extensive (up to 41 weeks) chase period, during which mice received normal chow ([Figure 3B](#fig3){ref-type="fig"}). This labeling strategy resulted in labeling of virtually all candidate HSCs ([Figure 3C](#fig3){ref-type="fig"}). The blood of labeled mice was analyzed regularly to determine the fraction of Tomato^+^ cells in PB cell subsets ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). Similar to after 1x Tamoxifen labeling, we observed robust label progression into all PB cell subsets, with similar kinetics in between different lineages ([Figure 3B](#fig3){ref-type="fig"}). However, a more complete HSC labeling resulted in a somewhat faster and more robust label progression into all PB cell subsets compared to 1x Tamoxifen labeling ([Figure 2E](#fig2){ref-type="fig"}). This was most evident for the lymphoid lineages, where the majority of PB cells had been generated from HSCs at the experiment end point upon prolonged Tamoxifen administration, whereas the ratio of labeled lymphocytes vs. labeled HSCs was low (\>0,5) even after 83 weeks of chase in 1x Tamoxifen labeled mice ([Figure 2B](#fig2){ref-type="fig"}, [Figure 2E](#fig2){ref-type="fig"} and [Figure 3B](#fig3){ref-type="fig"}).

From endpoint mice in which the pool of HSCs was almost completely labeled ([Figure 3C](#fig3){ref-type="fig"}), we next interrogated the skin epidermis for Tomato^+^ contribution to granulocytes and Langerhans cells. Granulocytes were almost completely Tomato positive, while Langerhans cells were devoid of label ([Figure 3D](#fig3){ref-type="fig"}, lower left), in line with the fetal origin and self-maintenance of the latter cells ([@bib16]). Next, we interrogated Tomato expression in Vγ3δ^+^ T cells, an established fetal derived T cell subset ([@bib25]). To our surprise, this revealed robust Tomato labeling of Vγ3δ^+^ T cells ([Figure 3D](#fig3){ref-type="fig"}, lower left). However, closer examination revealed high expression of ZsGreen in these cells ([Figure 3B](#fig3){ref-type="fig"}, lower middle). Therefore, rather than establishing adult contribution to this lineage, these experiments established Fgd5-CreERT2 transgene expression in Vγ3δ^+^ T cells.

B1a B cells represent an invariant subtype of B cells with a fetal origin that is primarily located in the peritoneum ([@bib26]), where they co-exists with more traditional B1b and B2 B cells in adult mice. While less than 10% of B1a B cells displayed Tomato label, around 50% of B1b B cells and the vast majority of B2 B cells ([Figure 3D](#fig3){ref-type="fig"} right) were Tomato^+^ (comparable to levels in PB). This is in line with a more strict fetal/postnatal origin of B1a B cells, the ontogenically mixed origin of B1b B cells ([@bib27]) and an adult HSC origin of most B2 B cells.

Finally, we investigated adult HSC contribution to microglial cells of the brain, a subset of central nervous system myeloid cells that has been proposed to arise entirely from embryonic precursor cells ([@bib4]). Evaluations by confocal microscopy of the brain parenchyma revealed no detectable Tomato expression in IBA-1^+^ microglia ([Figure 3E](#fig3){ref-type="fig"}), while Fgd5 expressing endothelial cells ([@bib15]; [@bib21]) displayed abundant Tomato expression ([Figure 3E](#fig3){ref-type="fig"} middle).

Native hematopoiesis from HSCs declines with aging {#s2-4}
--------------------------------------------------

We next set out to investigate how chronological aging influence on HSC contribution to hematopoiesis. To achieve rapid and robust labeling of HSCs, we labeled juvenile and aged *Fgd5^CreERT2/+^; Rosa26^lsl-Tomato/+^* mice by injecting Tamoxifen for five consecutive days (5x). Labeling was followed by evaluation of the fraction of Tomato positive cells in HSC and MPP fractions of the BM LSK compartment one day after the last Tamoxifen injection.

In aged mice, the initial labeling was highly specific to HSCs, with only low levels of labeling in MPP^2^ cells. In sharp contrast, a larger fraction of LSKCD150^-^CD48^-^ MPPs were labeled in juvenile mice ([Figure 4A](#fig4){ref-type="fig"}). Next, we correlated how increasing age influences on the HSC generation of other LSK/MPP subsets. *Fgd5^CreERT2/+^; Rosa26^lsl-Tomato/+^* mice between 6 and 96 weeks of age were labeled using a 5x Tamoxifen injection scheme, before evaluation of Tomato label in HSCs/MPP^2-4^21 days later. Ratios of the fraction of labeled MPPs vs. labeled HSCs in corresponding mice was calculated and plotted against mouse age at labeling ([Figure 4B](#fig4){ref-type="fig"}). This established that label progression into all MPP subsets in aged mice was substantially lower when compared to young adult mice and further revealed that the HSC contribution to MPPs and MPP^3/4^s gradually declines with age towards very little replenishment of in particular MPP^3/4^ in very old age ([Figure 4B](#fig4){ref-type="fig"}).

![Fgd5 mediate lineage tracing reveals gradually declining HSC contribution to hematopoiesis with age.\
(**A**) Cohorts of aged (11--12 months; n = 3) or young (23--25 days; n = 5,) *Fgd5^CreERT2/+^; Rosa26^lsl-Tomato/+^* mice were injected with Tamoxifen 5 times on consecutive days and analyzed for Tomato label in LSK-HSPCs on day 6. Bars indicate median %. (**B**) *Fgd5^CreERT2/+^; Rosa26^lsl-Tomato/+^* mice were injected with Tamoxifen for 5 consecutive days and analyzed for Tomato label in LSK-HSPCs 21 days later. The % of Tomato^+^ cells in MPP^2-4^ was divided by the % of Tomato^+^ HSCs in corresponding mice to determine the ratio of Tomato^+^ cells relative to HSCs. Ratios are plotted according to the age of mice at the time of Tamoxifen injection. (**C**) Indicated LSK subsets were isolated from *Fgd5^CreERT2/+^; Rosa26^lsl-Tomato/+^* mice and transplanted into WT mice on continuous Tamoxifen. Multilineage hematopoiesis and Tomato contribution was assed in PB 4, 8, 12 and 16 weeks after transplantation. Values in parenthesis indicate the number of mice with Tomato^+^ offspring. (**D**) Young (29 days; n = 3) and old (16 months; n = 4) *Fgd5^CreERT2/+^; Rosa26^lsl-Tomato/+^* mice were injected once with Tamoxifen and analyzed for Tomato label 18 weeks later. The % of Tomato^+^ cells in each indicated cell type was divided by the % of Tomato^+^ HSCs in corresponding mice to determine the ratio of Tomato^+^ cells relative to HSCs. (**E**) Model depicting HSC contribution to native hematopoiesis. Arrow weights and arrow lengths indicate the magnitude and the kinetics of HSC contribution to the indicated cell type respectively. The declining HSC contribution to hematopoiesis with age can be traced to a reduced differentiation of HSCs to MPPs (red arrows).](elife-41258-fig4){#fig4}

To evaluate the functional potential of initially Tomato-labeled MPPs, we FACS sorted HSCs and different MPP subsets isolated from non-labeled *Fgd5^CreERT2/+^; Rosa26^lsl-Tomato/+^* mice and transplanted cells into lethally irradiated wild type mice. Recipient mice were provided Tamoxifen containing food pellets throughout the experiment. We analyzed donor chimerism and Tomato labeled PB cells after repetitive PB blood sampling. As expected, we did not observe any multilineage long-term reconstitution or Tomato^+^ cells in MPP^2^/MPP^3/4^ transplanted mice ([Figure 4C](#fig4){ref-type="fig"}). 10 out of 10 HSC transplanted mice were multi lineage reconstituted at 16 weeks post transplantation with high levels of Tomato^+^ donor cells in all evaluated lineages ([Figure 4C](#fig4){ref-type="fig"}). More surprisingly 2 out of 9 MPP transplanted mice displayed donor reconstitution levels \> 1% in all lineages 16 weeks after transplantation ([Figure 4C](#fig4){ref-type="fig"}). This long-term multilineage reconstitution potential from MPPs was accompanied with robust Tomato labeling among donor cells and revealed that Tomato labeled phenotypic MPPs perform as bona fide HSCs after transplantation ([Figure 4C](#fig4){ref-type="fig"}). By contrast, mice that received MPP cells and displayed only transient myeloid reconstitution never displayed any Tomato^+^ cells. This demonstrates, in young mice, the presence of a minor CD150^-^ HSC activity that appears exclusively coupled to Fgd5 expression.

Finally, we were interested in determining whether the age-related decrease in HSC derived MPPs might influence on the generation kinetics of lineage-restricted progenitors and mature blood cells. For this, we labeled juvenile (29 days) and aged (87--89 weeks) *Fgd5^CreERT2/+^; Rosa26^lsl-Tomato/+^* mice with 1x Tamoxifen, which was followed by evaluation of label progression after 18 weeks ([Figure 4D](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). While the frequency of Tomato labeled HSCs was similar among the two groups ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), all progeny exhibited reduced frequencies of Tomato labeled cells in aged mice, demonstrating a strikingly reduced multilineage differentiation capacity of HSCs as a consequence of age.

Discussion {#s3}
==========

In this work, we explored the cellular contribution from HSCs using a HSC-specific lineage tracing approach. Our work revealed robust HSC contribution to adult multilineage hematopoiesis and, while not focused at studying fetal hematopoiesis, support the previously reported fetal/juvenile origins of several other specific hematopoietic subsets. We observed the fastest label progression into the platelet lineage, which might be related to the recent observations that at least a subset of HSCs appears platelet-biased ([@bib41]; [@bib44]). Thereafter, erythrocytes and granulocytes acquired label with similar kinetics, although Tomato^+^ erythrocytes emerged in the peripheral blood somewhat later than granulocytes. This likely reflects the slower turnover of mature erythrocytes compared to other myeloid cells. On the other hand, among granulocytes, we did not find any noticeable differences when evaluating HSC contribution to the neutrophil or eosinophil lineages (data not shown), despite the seemingly distinct transcriptional underpinnings of these lineages ([@bib17]).

Among lymphocytes, the HSC contribution was most rapid and robust to the NK cell lineage. At present, we can say little on whether this reflects an early and distinct progenitor intermediate for NK cells ([@bib55]) or whether NK cells are, at least partially, regenerated through myeloid progenitors ([@bib13]; [@bib23]). While the extremely slow HSC generation of adaptive immune components (and T cells in particular) have implications for our understanding of HSCs, by proposing that adult HSCs to a large extent present as myeloid-biased in an unperturbed scenario, our results also suggest the necessity of very harsh conditioning to achieve an 'immunological reboot' (the generation of naïve lymphocytes) in certain autoimmune situations ([@bib6]).

According to current models of hematopoiesis, lineage committed progenitors reside developmentally in between HSCs and their mature progeny, and much work has been aimed at detailing these stages ([@bib2]; [@bib3]; [@bib5]; [@bib33]; [@bib36]; [@bib37]). What has remained more unknown is the relationships of these defined progenitors not only to HSCs and their mature offspring, but also whether they are obligatory. In our work, we could demonstrate that the generation rates of each evaluated myeloid progenitor subset correlated highly to their corresponding mature offspring, although the generation kinetics varied depending on lineage. Thus, although some challenges have recently been raised on how lineage commitment occur from HSCs based on inferences from large-scale single-cell RNA sequencing experiments ([@bib35]; [@bib51]), our data support the more conventional view that the generation of mature myeloid cells is preceded by the generation of obligatory lineage-committed intermediates.

Investigations of immature progenitors revealed that the most rapid label progression associated with LSKCD150^-^CD48^-^ MPPs. MPPs share many defining properties of HSCs, including multilineage differentiation potential and very low proliferation rates in steady state ([@bib43]). The distinction of MPPs from HSCs is mainly thought to result from pronounced differences in self-renewal; a property so far entirely evaluated by transplantation. Intriguingly, our work revealed that LSKCD150^-^CD48^-^ MPPs displayed more rapid label kinetics in young mice, which was gradually declining with advancing age. At the same time, we could in agreement with previous studies ([@bib52]) also demonstrate a minor multilineage HSC activity in this compartment, which correlated exclusively to Fgd5 expression/Tomato labeling. Together with an overall decline in multilineage HSC contribution of aged mice, these results strongly propose a model in which aging associates with reduced/compromised HSC differentiation, which in combination with the well-established expansion of HSCs with age ([@bib32]; [@bib39]; [@bib46]) appears to represent a physiologically relevant compensatory mechanisms to sustain multilineage hematopoiesis from HSCs ([Figure 4E](#fig4){ref-type="fig"}).

Compared to MPPs, MPP^3/4^ are perhaps easier to approach given their restrictions in lineage potential (lack of Meg/E potential) ([@bib2]; [@bib5]; [@bib36]; [@bib37]). We found MPP^3/4^ to be regenerated from HSCs with slow kinetics compared to other downstream myeloid progenitor cells, but also to MPP^2^ cells, that we in agreement with other studies ([@bib36]) find 'primed' towards Meg/E development. Intriguingly, our data proposes a significant self-renewal activity of at least a subset of MPP^3/4^, with the demonstration that this fraction never reached label equilibrium with HSCs in any evaluated experimental setting. This might be particularly relevant in the setting of age, a situation in which HSC was found to generate MPP^3/4^ very inefficiently ([Figure 4E](#fig4){ref-type="fig"}).

While limited, a few groups have recently approached HSC contribution to native hematopoiesis. Evaluations of hematopoiesis using transposon mobilization led to the conclusion that HSCs are not major contributors to adult hematopoiesis ([@bib47]). To some degree, this conclusion was later corroborated by CreER-mediated labeling of a minor fraction of the adult HSC pool using a Tie2-based CreER driver ([@bib12]). Limited HSC contribution to adult hematopoiesis is in sharp contrast to the results we present here and to results from another recent study ([@bib42]). Our studies would propose that absence of a HSC specific driver, as in the work from Sun et al., makes interpretations of HSC contribution very complicated, not the least for the lymphoid lineages, while the labeling of only a minor fraction of HSCs, as in the work from Busch et al., might select for a subset of HSCs with a rather distinct functional behavior.

In summary, we conclude that although the study of native hematopoiesis highlights fundamental differences, with in particular slower regeneration times from HSCs to those seen after transplantation, they regardless corroborate decades of research derived from transplantation experiments in which HSCs has been proposed to continuously contribute to hematopoiesis.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\      Designation          Source or\                                                                Identifiers                                                              Additional\
  (species)\                              reference                                                                                                                                          information
  or resource                                                                                                                                                                                
  ------------------ -------------------- ------------------------------------------------------------------------- ------------------------------------------------------------------------ -------------
  Strain, strain\    *Fgd5-CreERT2*       PMID:24958848                                                             RRID:[IMSR_JAX:027789](https://scicrunch.org/resolver/IMSR_JAX:027789)   
  background\                                                                                                                                                                                
  (M. musculus)                                                                                                                                                                              

  Strain, strain\    *Rosa26-rtTA;*\      PMID:17554301                                                             RRID:[IMSR_JAX:014602](https://scicrunch.org/resolver/IMSR_JAX:014602)   
  background\        *Col1a1-tetO-*\                                                                                                                                                         
  (M. musculus)      *H2B-mCherry*\                                                                                                                                                          

  Strain, strain\    *Rosa26-*\           PMID:20023653                                                             RRID:[IMSR_JAX:007905](https://scicrunch.org/resolver/IMSR_JAX:007905)   
  background\        *Lox-Stop-*\                                                                                                                                                            
  (M. musculus)      *Lox-Tomato*                                                                                                                                                            

  Antibody           B220 PECy5           Biolegend                                                                 RRID:[AB_312994](https://scicrunch.org/resolver/AB_312994)               (1:400)

  Clone: RA3-6B2                                                                                                                                                                             

  Antibody           B220 biotin          Biolegend                                                                 RRID:[AB_312989](https://scicrunch.org/resolver/AB_312989)               (1:200)

  Clone: RA3-6B2                                                                                                                                                                             

  Antibody           B220 APC             Biolegend                                                                 RRID:[AB_312997](https://scicrunch.org/resolver/AB_312997)               (1:400)

  Clone: RA3-6B2                                                                                                                                                                             

  Antibody           CD105 PECy7          Biolegend                                                                 RRID:[AB_1027700](https://scicrunch.org/resolver/AB_1027700)             (1:200)

  Clone: MJ7/18                                                                                                                                                                              

  Antibody           CD115 BV605          Biolegend                                                                 RRID:[AB_2562760](https://scicrunch.org/resolver/AB_2562760)             (1:200)

  Clone: CSF-1R                                                                                                                                                                              

  Antibody           CD11b PECy5          Biolegend                                                                 RRID:[AB_312793](https://scicrunch.org/resolver/AB_312793)               (1:400)

  Clone: M1/70                                                                                                                                                                               

  Antibody           CD11b biotin         Biolegend                                                                 RRID:[AB_312787](https://scicrunch.org/resolver/AB_312787)               (1:200)

  Clone: M1/70                                                                                                                                                                               

  Antibody           CD11b APC            Biolegend                                                                 RRID:[AB_312795](https://scicrunch.org/resolver/AB_312795)               (1:800)

  Clone: M1/70                                                                                                                                                                               

  Antibody           CD11b APC-Cy7        Biolegend                                                                 RRID:[AB_830641](https://scicrunch.org/resolver/AB_830641)               (1:200)

  Clone: M1/70                                                                                                                                                                               

  Antibody           CD11c BV570          Biolegend                                                                 RRID:[AB_10900261](https://scicrunch.org/resolver/AB_10900261)           (1:200)

  Clone: N418                                                                                                                                                                                

  Antibody           CD150 APC            Biolegend                                                                 RRID:[AB_493460](https://scicrunch.org/resolver/AB_493460)               (1:400)

  Clone:\                                                                                                                                                                                    
  TC15-12F12.2                                                                                                                                                                               

  Antibody           CD150 PE             Biolegend                                                                 RRID:[AB_313683](https://scicrunch.org/resolver/AB_313683)               (1:200)

  Clone:\                                                                                                                                                                                    
  TC15-12F12.2                                                                                                                                                                               

  Antibody           CD16/32 AL700        eBioscience                                                               RRID:[AB_493994](https://scicrunch.org/resolver/AB_493994)               (1:100)

  Clone: 93                                                                                                                                                                                  

  Antibody           CD19 PECy7           eBioscience                                                               RRID:[AB_657663](https://scicrunch.org/resolver/AB_657663)               (1:200)

  Clone: 1D3                                                                                                                                                                                 

  Antibody           CD19 BV-786          BD-Horizon                                                                RRID:[AB_2738141](https://scicrunch.org/resolver/AB_2738141)             (1:200)

  Clone: 1D3                                                                                                                                                                                 

  Antibody           CD25 APC             eBioscience                                                               RRID:[AB_469366](https://scicrunch.org/resolver/AB_469366)               (1:100)

  Clone: PC 61.5                                                                                                                                                                             

  Antibody           CD31 PerCpCy5.5      Biolegend                                                                 RRID:[AB_2566761](https://scicrunch.org/resolver/AB_2566761)             (1:200)

  Clone: MEC13.3                                                                                                                                                                             

  Antibody           CD3e PECy5           Biolegend                                                                 RRID:[AB_312675](https://scicrunch.org/resolver/AB_312675)               (1:400)

  Clone:\                                                                                                                                                                                    
  145--2 C11                                                                                                                                                                                 

  Antibody           CD3e biotin          Biolegend                                                                 RRID:[AB_2563947](https://scicrunch.org/resolver/AB_2563947)             (1:200)

  Clone: 17A2                                                                                                                                                                                

  Antibody           CD3 AL700            Biolegend                                                                 RRID:[AB_493697](https://scicrunch.org/resolver/AB_493697)               (1:200)

  Clone: 17A2                                                                                                                                                                                

  Antibody           CD4 BV711            Biolegend                                                                 RRID:[AB_2562607](https://scicrunch.org/resolver/AB_2562607)             (1:200)

  Clone: RM4-5                                                                                                                                                                               

  Antibody           CD4 APC eFl780       eBioscience                                                               RRID:[AB_1272219](https://scicrunch.org/resolver/AB_1272219)             (1:200)

  Clone: RM4-5                                                                                                                                                                               

  Antibody           CD41 PerCP-eFl710    eBioscience                                                               RRID:[AB_10855042](https://scicrunch.org/resolver/AB_10855042)           (1:200)

  Clone: MWReg30                                                                                                                                                                             

  Antibody           CD45.1 AL700         Biolegend                                                                 RRID:[AB_493733](https://scicrunch.org/resolver/AB_493733)               (1:200)

  Clone: A20                                                                                                                                                                                 

  Antibody           CD45.2 PECy7         Biolegend                                                                 RRID:[AB_1186098](https://scicrunch.org/resolver/AB_1186098)             (1:200)

  Clone: 104                                                                                                                                                                                 

  Antibody           CD45.2 PE/\          Biolegend                                                                 RRID:[AB_2564177](https://scicrunch.org/resolver/AB_2564177)             (1:200)
                     Dazzle                                                                                                                                                                  

  Clone: 104                                                                                                                                                                                 

  Antibody           CD45.2 BV785         Sony                                                                      RRID:[AB_2562604](https://scicrunch.org/resolver/AB_2562604)             (1:200)

  Clone: 104                                                                                                                                                                                 

  Antibody           CD45.2 biotin        Biolegend                                                                 RRID:[AB_313441](https://scicrunch.org/resolver/AB_313441)               (1:200)

  Clone: 104                                                                                                                                                                                 

  Antibody           CD48 PECy7           Biolegend                                                                 RRID:[AB_2075049](https://scicrunch.org/resolver/AB_2075049)             (1:200)

  Clone:\                                                                                                                                                                                    
  HM48-1                                                                                                                                                                                     

  Antibody           CD48 AL700           Biolegend                                                                 RRID:[AB_10612755](https://scicrunch.org/resolver/AB_10612755)           (1:200)

  Clone:\                                                                                                                                                                                    
  HM48-1                                                                                                                                                                                     

  Antibody           CD5 BV-421           BD-Horizon                                                                RRID:[AB_2737758](https://scicrunch.org/resolver/AB_2737758)             (1:200)

  Clone: 53--7.3                                                                                                                                                                             

  Antibody           CD8 PerCpCy5.5       Sony                                                                      RRID:[AB_2075239](https://scicrunch.org/resolver/AB_2075239)             (1:200)

  Clone: 53--6.7                                                                                                                                                                             

  Antibody           c-kit APCeFl780      eBioscience                                                               RRID:[AB_1272177](https://scicrunch.org/resolver/AB_1272177)             (1:200)

  Clone: 2B8                                                                                                                                                                                 

  Antibody           c-kit APC            Biolegend                                                                 RRID:[AB_313221](https://scicrunch.org/resolver/AB_313221)               (1:100)

  Clone: 2B8                                                                                                                                                                                 

  Antibody           F4/80 BV421          Biolegend                                                                 RRID:[AB_11203717](https://scicrunch.org/resolver/AB_11203717)           (1:200)

  Clone: BM8                                                                                                                                                                                 

  Antibody           Flt3 biotin          eBioscience                                                               RRID:[AB_466600](https://scicrunch.org/resolver/AB_466600)               (1:200)

  Clone: AZF10                                                                                                                                                                               

  Antibody           Gr1 PECy5            Biolegend                                                                 RRID:[AB_313375](https://scicrunch.org/resolver/AB_313375)               (1:400)

  Clone: RB6-8C5                                                                                                                                                                             

  Antibody           Gr1 FITC             BD PH                                                                     RRID:[AB_394643](https://scicrunch.org/resolver/AB_394643)               (1:400)

  Clone: RB6-8C5                                                                                                                                                                             

  Antibody           Gr1 biotin           Biolegend                                                                 RRID:[AB_313369](https://scicrunch.org/resolver/AB_313369)               (1:200)

  Clone: RB6-8C5                                                                                                                                                                             

  Antibody           Gr1 BV711            Sony                                                                      RRID:[AB_2562549](https://scicrunch.org/resolver/AB_2562549)             (1:200)

  Clone: RB6-8C5                                                                                                                                                                             

  Antibody           IL7Ra BV510          Sony                                                                      RRID:[AB_2564576](https://scicrunch.org/resolver/AB_2564576)             (1:200)

  Clone: A7R34                                                                                                                                                                               

  Antibody           Ly6G APC/Fire750     Biolegend                                                                 RRID:[AB_2616733](https://scicrunch.org/resolver/AB_2616733)             (1:200)

  Clone: 1A8                                                                                                                                                                                 

  Antibody           NK1.1 PECy5          Biolegend                                                                 RRID:[AB_493591](https://scicrunch.org/resolver/AB_493591)               (1:400)

  Clone: PK136                                                                                                                                                                               

  Antibody           NK1.1 Pacific Blue   Biolegend                                                                 RRID:[AB_2132712](https://scicrunch.org/resolver/AB_2132712)             (1:200)

  Clone: PK136                                                                                                                                                                               

  Antibody           Sca1 Pacific Blue    Biolegend                                                                 RRID:[AB_2143237](https://scicrunch.org/resolver/AB_2143237)             (1:200)

  Clone: E13-161.7                                                                                                                                                                           

  Antibody           TcR Vγ3 APC          Biolegend                                                                 RRID:[AB_10895900](https://scicrunch.org/resolver/AB_10895900)           (1:200)

  Clone: 536                                                                                                                                                                                 

  Antibody           TcR γ/δ BV605        Biolegend                                                                 RRID:[AB_2563356](https://scicrunch.org/resolver/AB_2563356)             (1:200)

  Clone: GL3                                                                                                                                                                                 

  Antibody           Ter119 PECy5         Biolegend                                                                 RRID:[AB_313711](https://scicrunch.org/resolver/AB_313711)               (1:400)

  Clone: Ter-119                                                                                                                                                                             

  Antibody           Ter119 biotin        Biolegend                                                                 RRID:[AB_313705](https://scicrunch.org/resolver/AB_313705)               (1:200)

  Clone: Ter-119                                                                                                                                                                             

  Antibody           Ter119 PerCpCy5.5    Biolegend                                                                 RRID:[AB_893636](https://scicrunch.org/resolver/AB_893636)               (1:200)

  Clone: Ter-119                                                                                                                                                                             

  Peptide,\          Streptavidin\        Biolegend                                                                                                                                          (1:400)
  recombinant\       BV605                                                                                                                                                                   
  protein                                                                                                                                                                                    

  Peptide,\          Streptavidin-\       PMID:\                                                                                                                                             
  recombinant\       Saporin              27272386\                                                                                                                                          
  protein                                 Advanced\                                                                                                                                          
                                          Targeting\                                                                                                                                         
                                          Systems                                                                                                                                            

  Chemical\          Tamoxifen            Sigma-\                                                                   I.p. 50 mg/kg                                                            
  compound,\                              Aldrich                                                                                                                                            
  drug                                                                                                                                                                                       

  Chemical\          Doxycycline          Ssniff\                                                                   Food 2 g/kg                                                              
  compound,\                              Spezialdiäten                                                                                                                                      
  drug                                                                                                                                                                                       

  Chemical\          Tamoxifen            Ssniff\                                                                   Food\                                                                    
  compound,\                              Spezialdiäten                                                             400 mg/kg\                                                               
  drug                                                                                                              Tamoxifen\                                                               
                                                                                                                    Citrate                                                                  

  Software,\         Flowjo               FlowJo\                                                                   RRID:[S](https://scicrunch.org/resolver/SCR_008520)\                     
  algorithm                               ([https://www.](https://www.flowjo.com/solutions/flowjo)\                 [CR_008520](https://scicrunch.org/resolver/SCR_008520)                   
                                          [flowjo.com/solutions/flowjo](https://www.flowjo.com/solutions/flowjo))                                                                            

  Software,\         Microsoft\           Microsoft\                                                                RRID:\                                                                   
  algorithm          Excel                Excel\                                                                    [SCR_016137](https://scicrunch.org/resolver/SCR_016137)                  
                                          (<https://www.microsoft.com/en-gb/>)                                                                                                               

  Software,\         Graphpad\            GraphPad\                                                                 RRID:\                                                                   
  algorithm          Prism                Prism (<https://graphpad.com>)                                            [SCR_002798](https://scicrunch.org/resolver/SCR_002798)                  
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mouse procedures {#s4-1}
----------------

For inducible marking of HSCs in vivo, we crossed *Fgd5-2A-ZsGreen-CreERT2* mice ([@bib21]) (JAX 027789) to *Rosa26-LoxP-Stop-LoxP-Tomato* ([@bib31]) (JAX 007905) mice, resulting in *Fgd5^CreERT2/+^; Rosa26^lsl-Tomato/+^* mice. For simultaneous in vivo tracking of proliferation history and marking of HSCs, *Fgd5^CreERT2/+^; Rosa26^lsl-Tomato/+^* mice were crossed with *Col1a1^tetO-H2B-mCherry/tetO-H2B-mCherry^; ROSA26^rtTA/rtTA^* mice (JAX 014602) to generate *Fgd5^CreERT2/+^; Rosa26^lsl-Tomato/^*^rtTA^; *Col1a1^tetO-H2B-mCherry/+^*. Such mice were administered doxycycline in food pellets (2 g/kg; Ssniff Spezialdiäten) for 2 weeks followed by 5 weeks of chase before HSC marking by a single i.p. Tamoxifen injection (50 mg/kg) and analysis 5 days later.

Tamoxifen was purchased from Sigma-Aldrich and suspended at 100 mg/ml in ethanol and mixed with sunflower oil to a concentration of 10 mg/ml. Tamoxifen was administered by intraperitoneal injections at 50 mg/kg body weight once (1x) or for 5 (5x) consecutive days. To acquire full/maximal HSC labeling, cohorts of mice were continuously fed Tamoxifen containing food pellets for 16 weeks. Mice on Tamoxifen food were regularly bled (sparsely; 1--2 drops) during the labeling period and during the chase period.

Transplanted recipient mice were subjected to lethal irradiation (950 rad) except CD45.1/2 mice that were CD45-depleted by intravenous injection of an immunotoxin (3 mg/kg) consisting of CD45.2-biotin (clone 104) and streptavidin-Saporin (Advanced Targeting Systems) in a 1:1 molar ratio 3 days prior to transplantation, as described ([@bib34]). All transplanted cells were isolated from CD45.2 *Fgd5^CreERT2/+^; Rosa26^lsl-Tomato/+^* mice. CD45-depleted recipients were transplanted with 10^7^whole bone marrow (WBM) cells and irradiated mice were transplanted with 3 × 10^6^ WBM cells (n = 7), 200 (n = 10) or 100 (n = 2) HSCs, 635 MPPs (n = 10), 1200 MPP^2^s (n = 5) or 7300 MPP^3/4^s (n = 4). Tomato^+^ and Tomato^-^ HSCs were isolated from *Fgd5^CreERT2/+^; Rosa26^lsl-Tomato/+^* mice injected with Tamoxifen 2 days before isolation and transplantation into congenic C57BL/6 (CD45.1^+^) mice on normal chow. Before transplantations of HSCs or MPPs FACS sorted cells were mixed with 3 × 10^5^ WBM competitor cells in 200 µl PBS supplemented with 2 mM EDTA and 2% FBS before injection. Where indicated, recipient mice were given Tamoxifen containing food pellets (400 mg/kg Tamoxifen Citrate, Ssniff Spezialdiäten) throughout the experiments. At the indicated time point, PB was collected from the tail vein for reconstitution analysis.

H2B-mCherry labeling in *Col1a1^tetO-H2B-mCherry/tetO-H2B-mCherry^; ROSA26^rtTA/rtTA^* mice was induced by administration of doxycycline ([@bib43]). Thereafter, mice were chased for 5 weeks while eating Tamoxifen containing food pellets or normal chow (No TAM), followed by FACS analysis to assess H2B-mCherry dilution in HSCs/progenitors.

All mice were maintained at the animal facilities at BMC at Lund University and all experiments were performed with consent from the Malmö/Lund animal ethics board, reference number M186-15.

Immunophenotyping and FACS {#s4-2}
--------------------------

Immunophenotyping by FACS was done as described ([@bib43]) ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). For platelet and erythrocyte analysis, 1 μl of whole blood was taken to 300 μl PBS before FACS analysis. Cells were sorted and/or analyzed on a FACS Aria III cell sorter (Becton Dickinson) or on a LSRFortessa (Becton Dickinson).

B1a, Langerhans cells and Vg3^+^ T cell analysis {#s4-3}
------------------------------------------------

For isolation of peritoneal cells, peritoneal lavage was performed using 10 mL PBS. For isolation of skin epidermal cells, the flank of the mouse was shaved before excision of skin. The skin was incubated for 25 min at 37°C in a dissociation buffer (PBS containing 2.4 mg/ml of dispase (Roche) and 3% FCS) before separation of dermis from the epidermis. Pieces of epidermis were incubated for 30 min at 37°C in digestion buffer (PBS supplemented with 1 mg/ml collagenase IV \[Sigma-Aldrich\], 100 U/ml DNase I \[Sigma\], 2.4 mg/ml dispase \[Roche\] and 3% FBS) and thereafter filtered and stained against indicated markers. Before analysis, cells were incubated with Propidium Iodide (Invitrogen) to exclude dead cells.

Immunohistochemistry {#s4-4}
--------------------

Mice were deeply anaesthetized with an overdose of pentobarbital and transcardially perfused with cold saline. Brains were post-fixed for 48 hr in 4% paraformaldehyde (PFA) and incubated in 20% sucrose for 24 hr before being cut in 30 μm thick coronal sections on a microtome. Sections were incubated in blocking solution (5% normal serum and 0.25% Triton X-100 in 0.1 M potassium-phosphate buffered solution) for one hour and subsequently overnight at 4°C with the primary antibody (Iba1 1:1000 Wako). Fluorophore-conjugated secondary antibody (Molecular Probes or Jackson Laboratories) was diluted in blocking solution and applied for 2 hr at room temperature. Tomato label could be detected without any staining. Nuclei were stained with Hoechst (Molecular Probes) for 10 min and sections were mounted with Dabco mounting medium. Images were obtained using confocal microscopy (Zeiss, Germany).

Cell culture {#s4-5}
------------

Single LSKCD150^+^CD48^+^ cells, MPP^3/4^s and HSCs were sorted into Terasaki wells containing 20 μl of media (OptiMEM supplemented with 10% FCS, 1:1000 Gentamicin (Invitrogen), 1:100 GlutaMAX (Invitrogen) and 1:500 β-mercaptoethanol (Invitrogen) supplemented with cytokines (mSCF (Peprotech) 100 ng/ml, TPO (Peprotech) 10 ng/ml, IL-3 (Peprotech) 5 ng/ml, EPO (Janssen) 5units/ml, human G-CSF (Amgen) 10 ng/ml). After 6 days of culture at 37°C, wells were scored and evaluated for the presence of megakaryocytes and erythroid cells by visual inspection in microscope.

Gene expression analyses {#s4-6}
------------------------

qRT-PCR analyses using the Fluidigm Biomark HD Platform was done as described ([@bib43]) ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). PCA on gene expression data from all reference populations was performed using Clustvis, (<http://biit.cs.ut.ee/clustvis/>).

Single-cell RNA seq libraries were generated using a Chromium system (10x Genomics) according to the manufacturer's instructions. Two consecutive sequencing runs were performed to achieve enough sequencing depth and data was combined and further analyzed using the Cell Ranger^TM^ pipeline (10x Genomics). The accession number for the single-cell RNA sequencing data reported in this paper is GSE122473.

Statistical analysis {#s4-7}
--------------------

Data were analyzed using Microsoft Excel (Microsoft) and Graphpad Prism (GraphPad Software). All FACS analyses were performed using Flowjo software (TreeStar).
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Reviewing Editor
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United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"HSCs contribute actively to native multilineage hematopoiesis but with reduced differentiation capacity upon aging\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Sean Morrison as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

The manuscript by Säwén et al. uses an HSC-specific Fgd5 reporter mouse strain to investigate steady state mouse hematopoiesis. Using this method, the authors demonstrate that HSCs continuously give rise to multilineage hematopoiesis, with kinetics increasing from platelets, to erythrocytes, granulocytes, NK cells, B cells, and T cells. They also provide evidence that these mature cells are derived from intermediate progenitor cells that are the progeny of HSCs. Moreover, they corroborate recent studies demonstrating that a subset of hematopoietic cells including B1 B cells, Langerhans cells, and microglia are not derived from adult HSCs, but arise during fetal hematopoiesis. Finally, they show that HSC contribution to multilineage hematopoiesis declines with aging. These results are consistent with the classical model of hematopoiesis in which HSCs continuously give rise to multi-lineage hematopoiesis through intermediate lineage-restricted progenitors and contrast with several recent reports challenging this model. The observation that the contribution to hematopoiesis declines with age is very interesting.

1\) The authors highlight the recent publications on steady state mouse hematopoiesis by Sun et al. and Busch et al. which suggest that HSCs do not contribute significantly to multilineage blood production and that there can be long-term lineage restricted progenitors. The current results are in contrast to these other reports and the manuscript should highlight this distinction more clearly in the Abstract and Discussion.

2\) It is a little surprising that the percentage of Tomato^+^ progenitors is not higher even after 28 weeks post-induction in MPPs as well as other committed progenitors. This phenomenon could be due to only a subset of HSCs differentiating at any given time, as has been suggested by others such as Camargo, but it also raises the possibility that the Tomato protein somehow alters HPSC function. Indeed, there is such a suggestion of this in Figure 1F in the long-term reconstitution experiments since grafts from Tomato positive and negative HSCs do not appear the same with respect to% reconstitution (or possibly even lineage composition). In order to show that Tomato does not cause problems with differentiation, the authors should show that the lineage potential and total cell output does not differ between Tomato^+^ and negative HSCs and sorted progenitors. Such studies can be performed in differentiation/reconstitution assays in vitro or in vivo, and ideally this should be performed using HSCs from multiple independent donor mice. Related to this point, how many independent donors were used in Figure 1F? It seems that at least 3 independent donors (biological replicates) would be required to answer the question of whether or not there are differences in the reconstitution potential or lineage potential of Tomato^+^ and Tomato^-^ HSCs.

3\) Although the delayed contribution of old HSCs to MPPs is not surprising given that they are known to cycle slower than young HSCs, these experiments are only reliable if the Fgd5 reporter system works the same way in old HSCs as young; it does not appear the authors have confirmed this. In order to demonstrate this, the authors should show that Fgd5 expression is limited to HSCs in old mice and evaluate the distribution of Tomato labelling in the various types of HSCs (immunophenotypically defined My-bi, Balanced, Ly-bi) in old compared to young mice.

4\) The authors conclude their studies indicate that adult HSCs do not contribute significantly to several lineages (e.g. microglial cells, Langerhans cells), and they therefore conclude that such cells arise from fetal HSCs. It is not clear from the Materials and methods exactly when the HSCs were induced to express Tomato, but it is likely in mice \<8-10 weeks. Thus, while this speculation certainly is not unreasonable, at the same time these experiments were not designed in such a way to completely exclude this possibility. The authors are encouraged to be more circumspect with respect to the timing of the induction when making statements about whether or not post-natal HSCs may give rise to these cell populations. The Results and Discussion sections should be adjusted accordingly to mention this limitation of the studies.

10.7554/eLife.41258.018

Author response

> \[...\] 1) The authors highlight the recent publications on steady state mouse hematopoiesis by Sun et al. and Busch et al. which suggest that HSCs do not contribute significantly to multilineage blood production and that there can be long-term lineage restricted progenitors. The current results are in contrast to these other reports and the manuscript should highlight this distinction more clearly in the Abstract and Discussion.

We have changed the wording in both the Abstract and Discussion to more directly emphasize our quite different conclusions compared to those of Sun et al. and Busch et al.

> 2\) It is a little surprising that the percentage of Tomato^+^ progenitors is not higher even after 28 weeks post-induction in MPPs as well as other committed progenitors. This phenomenon could be due to only a subset of HSCs differentiating at any given time, as has been suggested by others such as Camargo, but it also raises the possibility that the Tomato protein somehow alters HPSC function. Indeed, there is such a suggestion of this in Figure 1F in the long-term reconstitution experiments since grafts from Tomato positive and negative HSCs do not appear the same with respect to% reconstitution (or possibly even lineage composition).
>
> In order to show that Tomato does not cause problems with differentiation, the authors should show that the lineage potential and total cell output does not differ between Tomato^+^ and negative HSCs and sorted progenitors. Such studies can be performed in differentiation/reconstitution assays in vitro or in vivo, and ideally this should be performed using HSCs from multiple independent donor mice. Related to this point, how many independent donors were used in Figure 1F? It seems that at least 3 independent donors (biological replicates) would be required to answer the question of whether or not there are differences in the reconstitution potential or lineage potential of Tomato^+^ and Tomato^-^ HSCs.

This is an insightful comment and we agree that the kinetic of replenishment of some multipotent progenitor subsets (especially GMLPs) is surprisingly slow. We interpret/discuss that this should reflect that some progenitors are imbued with a rather extensive self-renewal capability. A slow input to progenitor compartments from HSCs is also consistent with the preferential Tomato labeling of the least active HSCs by one Tamoxifen injection (Figure 1E).

While we don't believe that the Tomato protein per se alters HSPC function (see [Author response image 1](#respfig1){ref-type="fig"}), we however acknowledge that *Fgd5^CreERT2/+^* preferentially labels primitive/dormant HSCs after administration of lower doses of Tamoxifen. This is likely a consequence of higher Fgd5 expression in the most primitive HSCs (Säwén et al., 2016). We illustrate this in Figure 1E in our manuscript, which demonstrates preferential Tomato labeling by *Fgd5^CreERT2/+^* of the most H2B-label retaining HSCs. We consider dormancy/quiescence as a hallmark property of HSCs with the highest reconstitution potential, a view supported by a large number of previous studies. In light of this, we do not think it is surprising that Tomato^+^ HSCs could have somewhat different reconstitution patterns than Tomato negative HSCs (Figure 1F).

In an attempt to make a more fair comparison, we have compared the behavior of Tomato^+^ HSCs (in Figure 1F) to LSK-SLAM HSCs with a more restricted proliferation history (Säwén et al., 2016) following transplantation. This revealed a highly similar lineage distribution from Tomato^+^ HSCs and Tomato^-^ HSCs (see [Author response image 1](#respfig1){ref-type="fig"}). One potential concern of this comparison is however the limited number of cells transplanted (5 cells and 10 cells, respectively, with rather limited numbers of mice/group). We therefore also compared the behavior of Tomato^+^ donor cells following reconstitution with 200 *Fgd5^CreERT2^* x Tomato HSCs (from Figure 4C in our manuscript) to a previous experiment in which we evaluated 100 HSCs isolated solely based on phenotype from WT mice (Supplementary information in Ugale et al., 2014). Also in this comparison, we observed no significant differences (2-tailed Student's t-test) in lineage reconstitution between Tomato^+^ and Tomato^-^ HSCs. Collectively, we have therefore little reason to suspect altered cellular function caused by Tomato protein expression per se.

![The Tomato fluorescent protein does not influence on the in vivo differentiation potential of HSCs.](elife-41258-resp-fig1){#respfig1}

> 3\) Although the delayed contribution of old HSCs to MPPs is not surprising given that they are known to cycle slower than young HSCs, these experiments are only reliable if the Fgd5 reporter system works the same way in old HSCs as young; it does not appear the authors have confirmed this. In order to demonstrate this, the authors should show that Fgd5 expression is limited to HSCs in old mice and evaluate the distribution of Tomato labelling in the various types of HSCs (immunophenotypically defined My-bi, Balanced, Ly-bi) in old compared to young mice.

This is of course a highly relevant comment as a differential expression of Fgd5 in old animals could underlie our findings. We note that we in our original manuscript provided limited information on this. We began to address the HSCs specificity of the *Fgd5^CreERT2/+^* system in aged animals in Figure 4A, where we investigated the Tomato labeling of HSPCs after 5 daily tamoxifen injections. This showed that among LSK cells, virtually all Tomato^+^ cells are HSCs (or perhaps more accurately phrased, have an HSC phenotype) in old animals.

In addition to CreERT2, the mouse strain we work with also express a ZsGreen fluorescent reporter protein from the Fgd5-locus (Figure 2B). We have now taken advantage of this and compared Fgd5-ZsGreen expression in young and old mice (see [Author response image 2](#respfig2){ref-type="fig"}). This revealed the highest Fgd5 expression in the CD150 highest HSCs (previously suggested to be myeloid-biased) both in young (8 weeks old) and aged (96 weeks old) mice, but also substantial expression of Fgd5 in CD150 intermediate HSCs ("Balanced"; in both young and old mice). A much more limited expression of Fgd5 is observed in CD150 negative candidate HSCs (Ly-bi). Compared to our previous work in which we defined HSC subtypes based on levels of CD150 (Beerman et al., 2010), we could here not include selection based on CD34-negativity (both because of technical incompatibilities but above all the well-established fact that levels of CD34 on HSCs fluctuate with activation). Not selecting for CD34-negativity likely underlies the differences in frequencies of these subsets in young/old mice (especially the larger fraction of CD150 negative cells) compared to our previous work (Beerman et al., 2010).

![The expression of Fgd5 in HSC subsets of young and old mice.](elife-41258-resp-fig2){#respfig2}

> 4\) The authors conclude their studies indicate that adult HSCs do not contribute significantly to several lineages (e.g. microglial cells, Langerhans cells), and they therefore conclude that such cells arise from fetal HSCs. It is not clear from the Materials and methods exactly when the HSCs were induced to express Tomato, but it is likely in mice \<8-10 weeks. Thus, while this speculation certainly is not unreasonable, at the same time these experiments were not designed in such a way to completely exclude this possibility. The authors are encouraged to be more circumspect with respect to the timing of the induction when making statements about whether or not post-natal HSCs may give rise to these cell populations. The Results and Discussion sections should be adjusted accordingly to mention this limitation of the studies.

We thank the reviewers for this comment and completely agree that our original wording was inappropriate. Accordingly, we have made changes to the Results and Discussion:

Subsection title changed to "Fgd5-mediated HSC lineage tracing corroborates the fetal/juvenile origin of Langerhans cells, B1a B cells and brain microglial cells".

Subsection "Fgd5-mediated HSC lineage tracing corroborates the fetal/juvenile origin of Langerhans cells, B1a B cells and brain microglial cells": "This is in line with a more strict fetal/postnatal origin of B1a B cells."

Discussion section: "Our work revealed robust HSC contribution to adult multilineage hematopoiesis and, while not focused at studying fetal hematopoiesis, support the previously reported fetal/juvenile origins of several other specific hematopoietic subsets."
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